戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  and the putative neuroprotective effects of pergolide.
2                                Intracortical pergolide (1 microM, 60 min) was associated with a prolo
3 ptor agonists cabergoline (a D2 agonist) and pergolide (a D1/D2 agonist) administered in separate ses
4 d (a Bruton's tyrosine kinase inhibitor) and pergolide (a dopamine and serotonin receptor agonist) ro
5                                              Pergolide also caused vasoconstriction in rat pulmonary
6 irole, 7-hydroxy-dipropylamin-otetralin, and pergolide also induced sensitization, whereas the high a
7 e selective for D2-like receptors, with only pergolide and apomorphine potentially interacting with D
8 e and dexfenfluramine, the dopamine agonists pergolide and cabergoline, and more recently, the recrea
9                          We also report that pergolide and dihydroergotamine, two drugs recently demo
10                           The combination of pergolide and ondansetron normalized not only behavioral
11  Like low dopamine, the D3 receptor agonists pergolide and PD 128907 reduced MSR amplitude in WT but
12 determined that in this assay, piribedil and pergolide are full agonists for the recruitment of Galph
13  for the WT receptor using bromocriptine- or pergolide- as templates.
14 In this instance both the bromocriptine- and pergolide-based CoMFA models were similar to one another
15                                          The pergolide-based S193A model was more strikingly differen
16                                              Pergolide causes Kv channel inhibition and, despite bein
17 o and cabergoline conditions, but not in the pergolide condition.
18                                              Pergolide directly inhibited heterologously expressed Kv
19                                              Pergolide enhanced hypoxic pulmonary vasoconstriction in
20 eriments (e.g., during 10 microM dopamine or pergolide in WT), polysynaptic reflexes were facilitated
21 indings suggest that clinical monitoring for pergolide-induced PAH should be considered.
22                                              Pergolide inhibited PASMC potassium current density, res
23 tive dopamine receptor agonists SKF38393 and pergolide into the medial prefrontal cortex (mPfc) on lo
24                         In rats treated with pergolide mesylate (7 days 0.5 mg/kg/day, i.p.), the ave
25 -associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed
26 ted with pergolide use, we hypothesized that pergolide might have similar effects on hypoxic pulmonar
27                                              Pergolide produces clinical benefit in Parkinson disease
28                           This suggests that pergolide treatment leads to an increased ability of str
29    Although PAH has not been associated with pergolide use, we hypothesized that pergolide might have
30 eart valve disease (CLHVD) has been noted in pergolide users, reminiscent of that induced by certain
31                                              Pergolide was chosen as an alternate template because it